Trial drug reduces OA pain but may cause further joint damage
It is possible that the reduction in pain leads to increased weight-bearing on damaged joints
A new industry study shows that tanezumab is an effective analgesic for osteoarthritis but confirms an increased risk of rapidly progressive OA and total joint replacement seen in earlier trials.
Tanezumab is an investigational humanised monoclonal antibody that binds and inhibits nerve growth factor. It is being developed by Pfizer and Eli Lilly and Company, which funded the current trial.
